| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1701-2163(15)30568-5 |
| P698 | PubMed publication ID | 24927192 |
| P2093 | author name string | Jeff Nisker | |
| Meredith Vanstone | |||
| Barbra de Vrijer | |||
| Carol King | |||
| P2860 | cites work | Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood | Q24657306 |
| DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study | Q30414408 | ||
| Qualitative study of evidence based leaflets in maternity care | Q33958917 | ||
| Prenatal screening for fetal aneuploidy in singleton pregnancies | Q33958921 | ||
| Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis | Q34028063 | ||
| DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study | Q34029044 | ||
| Non-invasive prenatal measurement of the fetal genome | Q34286073 | ||
| From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges | Q34286705 | ||
| Non-invasive prenatal testing: ethical issues explored | Q34328617 | ||
| Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis | Q34399889 | ||
| The 50th anniversary of the discovery of trisomy 21: the past, present, and future of research and treatment of Down syndrome | Q34994416 | ||
| Motivations for undertaking DNA sequencing-based non-invasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong | Q35060714 | ||
| Circulating fetal DNA: its origin and diagnostic potential-a review | Q35699978 | ||
| Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review | Q35857896 | ||
| Noninvasive prenatal diagnosis of fetal Rhesus D: ready for Prime(r) Time | Q36274725 | ||
| Informed consent: providing information about prenatal examinations | Q36721064 | ||
| Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma | Q37010246 | ||
| Ethical aspects arising from non-invasive fetal diagnosis | Q37075330 | ||
| Women's accounts of the physical sensation of chorionic villus sampling and amniocentesis: expectations and experience | Q37165960 | ||
| Barriers and facilitators to implementing shared decision-making in clinical practice: update of a systematic review of health professionals' perceptions | Q37254654 | ||
| Complications after second trimester surgical and medical abortion | Q37260985 | ||
| The use of cell-free fetal nucleic acids in maternal blood for non-invasive prenatal diagnosis | Q37306246 | ||
| A measure of informed choice. | Q37331258 | ||
| Information and decision support needs of parents considering amniocentesis: interviews with pregnant women and health professionals. | Q37332556 | ||
| Challenging the rhetoric of choice in prenatal screening | Q37348789 | ||
| Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report | Q37466951 | ||
| Public Attitudes and Beliefs About Genetics | Q37778383 | ||
| Uses of cell free fetal DNA in maternal circulation | Q38006298 | ||
| Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma | Q38087410 | ||
| ACMG statement on noninvasive prenatal screening for fetal aneuploidy. | Q38096182 | ||
| Non-invasive prenatal testing for aneuploidy: current status and future prospects | Q38114375 | ||
| Fetal sex determination and disclosure | Q80255502 | ||
| Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening | Q81450492 | ||
| Non-invasive prenatal genetic testing: a study of public attitudes | Q82557190 | ||
| Genetics on stage: public engagement in health policy development on preimplantation genetic diagnosis | Q83387525 | ||
| Information-sharing to promote informed choice in prenatal screening in the spirit of the SOGC clinical practice guideline: a proposal for an alternative model | Q83561561 | ||
| Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy | Q85495453 | ||
| Embodied Knowledge and Making Sense of Prenatal Diagnosis | Q85528172 | ||
| A minimal set of SNPs for the noninvasive prenatal diagnosis of β-thalassaemia | Q86014130 | ||
| Training in chorionic villus sampling: limited experience for US fellows. | Q40472814 | ||
| What constitutes 'balanced' information in the practitioners' portrayals of Down's syndrome? | Q40627182 | ||
| Public viewpoints on new non-invasive prenatal genetic tests | Q43465721 | ||
| Clinical correlates of pain with amniocentesis | Q43507673 | ||
| Knowledge of prenatal screening and psychological management of test decisions | Q43894450 | ||
| First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing | Q43905798 | ||
| One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15 030 pregnancies | Q45078884 | ||
| Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis | Q46172895 | ||
| First-trimester or second-trimester screening, or both, for Down's syndrome | Q46799629 | ||
| The routine and the traumatic in prenatal genetic diagnosis: does clinical information inform patient decision-making? | Q47291099 | ||
| Women and health care professionals' preferences for Down's Syndrome screening tests: a conjoint analysis study | Q47307138 | ||
| Should non-invasiveness change informed consent procedures for prenatal diagnosis? | Q48866826 | ||
| Risk and uncertainty: shifting decision making for aneuploidy screening to the first trimester of pregnancy | Q50116949 | ||
| A meta-synthesis of pregnant women's decision-making processes with regard to antenatal screening for Down syndrome. | Q50727861 | ||
| Are pregnant Australian women well informed about prenatal genetic screening? A systematic investigation using the Multidimensional Measure of Informed Choice. | Q50926395 | ||
| Psychological outcome in women undergoing termination of pregnancy for ultrasound-detected fetal anomaly in the first and second trimesters: a pilot study. | Q50974597 | ||
| Maternal pain and anxiety in genetic amniocentesis: expectation versus reality. | Q51054609 | ||
| Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. | Q51349861 | ||
| Antenatal screening for Down's syndrome using the Integrated test at two London hospitals. | Q51836257 | ||
| First trimester combined screening for Trisomy 21 in Hong Kong: outcome of the first 10,000 cases. | Q51859975 | ||
| Practical and ethical considerations of noninvasive prenatal diagnosis. | Q51933954 | ||
| Informed decision making in the context of prenatal screening. | Q51961401 | ||
| Do pregnant women in Greece make informed choices about antenatal screening for Down's syndrome? A questionnaire survey. | Q51993722 | ||
| A novel amniocentesis model for learning stereotactic skills. | Q52024052 | ||
| Women's decisions about maternal serum screening testing: a qualitative study exploring what they learn and the role prenatal care providers play. | Q53112211 | ||
| Women's knowledge of prenatal ultrasound and informed choice. | Q53384893 | ||
| Facilitating informed choice in prenatal testing: how well are we doing? | Q53458334 | ||
| Bioethical concepts in theory and practice: an exploratory study of prenatal screening in Iceland | Q56777965 | ||
| Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals | Q56780865 | ||
| Presence of fetal DNA in maternal plasma and serum | Q57075132 | ||
| Favorable attitudes toward testing for chromosomal abnormalities via analysis of fetal cells in maternal blood | Q57506097 | ||
| Obstetricians presenting amniocentesis to pregnant women: Practice observed | Q57745721 | ||
| Women’s and health professionals’ preferences for prenatal tests for Down syndrome: a discrete choice experiment to contrast noninvasive prenatal diagnosis with current invasive tests | Q57839583 | ||
| Noninvasive prenatal testing for aneuploidy–ready for prime time? | Q57839590 | ||
| Medical Disparagement of the Disability Experience: Empirical Evidence for the “Expressivist Objection” | Q58307899 | ||
| Towards an ethical policy for the prevention of fetal sex selection in Canada | Q58668824 | ||
| Immediate adverse events after second trimester medical termination of pregnancy: results of a nationwide registry study | Q60311708 | ||
| Down syndrome screening: What do health professionals know? | Q61847048 | ||
| Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: relation to maternal and fetal characteristics | Q61847812 | ||
| Chromosome-selective sequencing of maternal plasma cell–free DNA for first-trimester detection of trisomy 21 and trisomy 18 | Q61847821 | ||
| Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population | Q61847837 | ||
| Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction | Q73015033 | ||
| Prenatal DNA diagnosis of a single-gene disorder from maternal plasma | Q73074402 | ||
| Antenatal screening for Down's syndrome with the quadruple test | Q73138939 | ||
| Proteinuria and hypertension are independent factors affecting fetal DNA values: a retrospective analysis of affected and unaffected patients | Q75227904 | ||
| Improvement in sensitivity of allele-specific PCR facilitates reliable noninvasive prenatal detection of cystic fibrosis | Q75424535 | ||
| A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A | Q77790082 | ||
| 'Because of the risks': how US pregnant women account for refusing prenatal screening | Q78024809 | ||
| Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model | Q78143639 | ||
| P433 | issue | 6 | |
| P921 | main subject | ethics policy | Q59812666 |
| P304 | page(s) | 515-526 | |
| P577 | publication date | 2014-06-01 | |
| P1433 | published in | Journal of Obstetrics and Gynaecology Canada | Q15761143 |
| P1476 | title | Non-invasive prenatal testing: ethics and policy considerations. | |
| P478 | volume | 36 |
| Q37624999 | "I think we've got too many tests!": Prenatal providers' reflections on ethical and clinical challenges in the practice integration of cell-free DNA screening. |
| Q64229494 | Canadian genetic healthcare professionals' attitudes towards discussing private pay options with patients |
| Q39387768 | Clinical, social and ethical issues associated with non-invasive prenatal testing for aneuploidy |
| Q61448634 | Facilitating informed choice about non-invasive prenatal testing (NIPT): a systematic review and qualitative meta-synthesis of women's experiences |
| Q89635382 | Implementation challenges for an ethical introduction of noninvasive prenatal testing: a qualitative study of healthcare professionals' views from Lebanon and Quebec |
| Q33634135 | Knowledge and Attitudes Regarding Non-Invasive Prenatal Testing (NIPT) and Preferences for Risk Information among High School Students in Sweden |
| Q57809529 | Limits to the scope of non-invasive prenatal testing (NIPT): an analysis of the international ethical framework for prenatal screening and an interview study with Dutch professionals |
| Q36777378 | Non-invasive Prenatal Testing (NIPT): Better Meet an Expert!: The Case of a Late Detected Trisomy 13 Reveals Structural Problems in NIPT Counselling and Highlights Substantial Risks for the Reproductive Autonomy |
| Q36184534 | Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening |
| Q26764809 | Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues |
| Q48094333 | Offering non-invasive prenatal testing as part of routine clinical service. Can high levels of informed choice be maintained? |
| Q64107405 | Preferences for aspects of antenatal and newborn screening: a systematic review |
| Q86800597 | The Latest Thorn by Any Other Name: Germ-Line Nuclear Transfer in the Name of "Mitochondrial Replacement" |
| Q47820038 | The Shifting Landscape of Prenatal Testing: Between Reproductive Autonomy and Public Health |
| Q58301130 | What Is “NIPT”? Divergent Characterizations of Noninvasive Prenatal Testing Strategies |
| Q33628632 | What do people want to know about NIPT? Content analysis of questions emailed to national NIPT information websites |
| Q38996878 | Women's Experiences of Publicly Funded Non-Invasive Prenatal Testing in Ontario, Canada: Considerations for Health Technology Policy-Making |
| Q52319943 | Women's perspectives on the ethical implications of non-invasive prenatal testing: a qualitative analysis to inform health policy decisions. |
Search more.